Indication

Mild to moderate Alzheimer's type dementia

Mild to moderate Alzheimer’s type dementia is an intermediate clinical stage of a progressive, neurodegenerative disorder of the central nervous system, predominantly affecting older adults. Read more about Mild to moderate Alzheimer's type dementia

87 drugs 63 manufacturers

Advertisement

Drugs that treat it

Common Mild to moderate Alzheimer's type dementia therapies.

Showing 19–27 of 87 drugs

GALANTAMINE HBR

MILD TO MODERATE ALZHEIMER'S TYPE DEMENTIA
Mylan Pharmaceuticals

GALANTAMINE HBR

ALZHEIMER'S DISEASE AGENTS·MILD TO MODERATE ALZHEIMER'S TYPE DEMENTIA
AUROBINDO PHARM
Filter & compare in the drug finder →Opens the drug finder with Mild to moderate Alzheimer's type dementia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Mild to moderate Alzheimer's type dementia.

Mild to moderate Alzheimer’s type dementia is an intermediate clinical stage of a progressive, neurodegenerative disorder of the central nervous system, predominantly affecting older adults.

Pathophysiologically, it is characterized by the accumulation of extracellular amyloid-beta plaques, intracellular hyperphosphorylated tau neurofibrillary tangles, synaptic dysfunction, and widespread neuronal loss.

Clinically, this phase features noticeable short-term memory deficits, executive dysfunction, language impairment, and disorientation that progressively erode autonomy.

While patients initially struggle with complex instrumental activities of daily living—such as managing finances or medications—the moderate stage brings worsening confusion, behavioral changes, and an emerging need for assistance with basic personal self-care.

Personalize your experience

Follow Mild to moderate Alzheimer's type dementia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it